Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Intravenous Veletri (epoprostenol) injection could be efficient in treating Raynaud’s phenomenon, a literature review published in the journal Annals of Pharmacotherapy has shown. In addition, according to the study, patients ... Read more
Iloprost, a drug used for secondary Raynaud’s phenomenon, might stop the development of new ulcers in the fingers, protect against heart and lung disease, and prevent the worsening of the ... Read more
A radiopharmaceutical technique can be used as an objective tool to diagnose Raynaud’s phenomenon (RP) and differentiate between primary and secondary RP, according to a study published in the journal ... Read more
Thenar and hypothenar hammer syndromes and Raynaud’s phenomenon can be successfully treated with iloprost injection according to a case study conducted by a team of researchers from Whales and Italy. ... Read more
A case study reported in the medical journal Oxford Medical Case Reports emphasizes the complexity of undifferentiated connective tissue diseases (UCTD), which correspond to a large spectrum of autoimmune disorders ... Read more